# Manufacture of Bulk Chemicals and Bulk Pharmaceutical Ingredients for Preclinical and Clinical Studies

> **NIH NIH N01** · ALCHEM LABORATORIES CORPORATION · 2020 · $432,304

## Abstract

The Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) supports the NCI's
Experimental Therapeutics (NExT) program to facilitate the transition of novel drug discoveries into clinical trials of
new cancer therapeutic agents. One of essential parts of the program involves the manufacture and supply of bulk
chemicals/drugs that are prepared under the current Good Manufacturing Practice (c-GMP). The bulk drugs will be
used to support pre-clinical studies and to prepare clinical products that are necessary to support human clinical trials
under the NCI sponsorship or investigator initiated INDs.

## Key facts

- **NIH application ID:** 10075834
- **Project number:** 261201700020C-P00007-9999-1
- **Recipient organization:** ALCHEM LABORATORIES CORPORATION
- **Principal Investigator:** SERGIY DENYSENKO
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $432,304
- **Award type:** —
- **Project period:** 2017-08-01 → 2020-06-04

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10075834

## Citation

> US National Institutes of Health, RePORTER application 10075834, Manufacture of Bulk Chemicals and Bulk Pharmaceutical Ingredients for Preclinical and Clinical Studies (261201700020C-P00007-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10075834. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*